Nimodipine, a calcium channel blocker, delays the spontaneous LH surge in women with regular menstrual cycles: a prospective pilot study

Reproductive Biology and Endocrinology

Robert F Casper²  Shany Klachook²  Dan Nayot¹ 

[1] Department of Obstetrics & Gynaecology, Mount Sinai Hospital, University of Toronto, 92 College Street, Toronto, Canada;Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada

关键词: Nimodipine;    Calcium channel blocker;    GnRH antagonist;    GnRH agonist;    In-vitro fertilization (IVF);    Premature LH surge;   

Others  :  828878
DOI  :  10.1186/1477-7827-11-7

 received in 2012-12-09, accepted in 2013-01-23,  发布年份 2013

【 摘 要 】

Background

Currently GnRH analogue injections are used to prevent premature LH surges in women undergoing assisted reproductive technology. This was a pilot study to determine the safety and effectiveness of nimodipine, an oral calcium channel blocker, to delay the mid-cycle spontaneous LH surge in women with regular menstrual cycles.

Methods

Eight women with regular menstrual cycles self-monitored three consecutive cycles for the day of an LH surge by daily urine assay. The first and third cycles were observatory. In the second cycle, subjects took nimodipine 60 mg by mouth three times daily for four days, starting two days prior to the expected LH surge day based on cycle one.

Results

The LH surge day in cycle 2 (nimodipine) was significantly delayed in comparison to both observatory cycle 1 (15.5+/−3.4 vs 14.0+/−2.8 days; p = 0.033) and cycle 3 (15.1+/−3.5 vs 13.1+/−2.4 days; p = 0.044). There was no difference in the LH surge day between the two observatory cycles (13.4+/−2.4 vs 13.1+/−2.4 days; p = 0.457). Three patients experienced a mild headache.

Conclusions

There was a statistically significant delay in the spontaneous LH surge day in the treatment cycle in comparison to both observatory cycles. Nimopidine should be further investigated as an oral alternative to delay a spontaneous LH surge.

【 授权许可】

   
2013 Nayot et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Pelinck MJ, Hoek A, Simons AH, Heineman MJ: Efficacy of natural cycle IVF: a review of the literature. Hum Reprod Update 2002, 8(2):129-139.
• [2]Hamori M, Stuckensen JA, Rumpf D, Kniewald T, Kniewald A, Kurz CS: Premature luteinization of follicles during ovarian stimulation for in-vitro fertilization. Hum Reprod 1987, 2(8):639-643.
• [3]Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Jenkins J, Pellicer A: Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod 2010, 25(8):2092-2100.
• [4]van Loenen AC, Huirne JA, Schats R, Hompes PG, Lambalk CB: GnRH agonists, antagonists, and assisted conception. Semin Reprod Med 2002, 20:349-364.
• [5]Sills ES, Collins GS, Salem SA, Jones CA, Peck AC, Salem RD: Balancing selected medication costs with total number of daily injections: a preference analysis of GnRH-agonist and antagonist protocols by IVF patients. Reprod Biol Endocrinol 2012, 10(1):67. BioMed Central Full Text
• [6]Núñez L, Villalobos C, Boockfor FR, Frawley LS: The relationship between pulsatile secretion and calcium dynamics in single, living gonadotropin-releasing hormone neurons. Endocrinology 2000, 141(6):2012-2017.
• [7]Merelli F, Stojilković SS, Iida T, Krsmanovic LZ, Zheng L, Mellon PL, Catt KJ: Gonadotropin-releasing hormone-induced calcium signaling in clonal pituitary gonadotrophs. Endocrinology 1992, 131(2):925-932.
• [8]Krsmanović LZ, Stojilković SS, Merelli F, Dufour SM, Virmani MA, Catt KJ: Calcium signaling and episodic secretion of gonadotropin-releasing hormone in hypothalamic neurons. Proc Natl Acad Sci 1992, 89(18):8462-8466.
• [9]Fukushima A, Sano A, Aiba S, Kimura F: Role of Na + and Ca2+ channels in the preoptic LH surge generating mechanism in proestrous rats. Endocr J 2003, 50(2):145-153.
• [10]van Zwieten PA, Pfaffendorf M: Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J Hypertens Suppl 1993, 11(6):S3-S8.
• [11]Ma B, Shang J: Nimodipine treatment to assess a modified mouse model of intracerebral hemorrhage. Brain Res 2006, 1078(1):182-188.
• [12]Nimotop: Product Monograph. Calcium channel blocking agent. Bayer Inc; 2008. [http://www.bayer.ca/files/NIMOTOP-TAB-PM-ENG-03NOV2011-148221.pdf webcite]
• [13]Leclerc GM, Boockfor FR: Calcium influx and DREAM protein are required for GnRH gene expression pulse activity. Mol Cell Endocrinol 2007, 267(1–2):70-79.
• [14]Chen EC, Javors MA, Norris C, Siler-Khodr T, Schenken RS, King TS: Dependence of 3’,5’-cyclic adenosine monophosphate–stimulated gonadotropin-releasing hormone release on intracellular calcium levels and L-type calcium channels in superfused GT1–7 neurons. J Soc Gynecol Investig 2004, 11(6):393-398.
• [15]Martinez de la Escalera G, Choi AL, Weiner RI: Signaling pathways involved in GnRH secretion in GT1 cells. Neuroendocrinology 1995, 61(3):310-317.
• [16]Fainaru O, Firestone R, Casper RF: Oral nimodipine inhibits the ovarian cycle in mice. Fertil Steril 2011, 95:1494-1496.
• [17]Antaki R, Dean NL, Lapensée L, Racicot MH, Ménard S, Kadoch IJ: An algorithm combining ultrasound monitoring and urinary luteinizing hormone testing: a novel approach for intrauterine insemination timing. J Obstet Gynaecol Can 2011, 33(12):1248-1252.
• [18]Cantineau AE, Cohlen BJ, Dutch IUI Study Group: The prevalence and influence of luteinizing hormone surges in stimulated cycles combined with intrauterine insemination during a prospective cohort study. Fertil Steril 2007, 88(1):107-112.
• [19]Palatnik A, Strawn E, Szabo A, Robb P: What is the optimal follicular size before triggering ovulation in intrauterine insemination cycles with clomiphene citrate or letrozole? An analysis of 988 cycles. Fertil Steril 2012, 97:1089-1094.
• [20]Miller BH, Olson SL, Levine JE, Turek FW, Horton TH, Takahashi JS: Vasopressin regulation of the proestrous luteinizing hormone surge in wild-type and Clock mutant mice. Biol Reprod 2006, 75(5):778-784.
• [21]Pierce BN, Clarke IJ, Turner AI, Rivalland ET, Tilbrook AJ: Cortisol disrupts the ability of estradiol-17beta to induce the LH surge in ovariectomized ewes. Domest Anim Endocrinol 2009, 36(4):202-208.
• [22]Wagenmaker ER, Breen KM, Oakley AE, Pierce BN, Tilbrook AJ, Turner AI, Karsch FJ: Cortisol interferes with the estradiol-induced surge of luteinizing hormone in the ewe. Biol Reprod 2009, 80(3):458-463.
• [23]Richter TA, Robinson JE, Lozano JM, Evans NP: Progesterone can block the preovulatory gonadotropin-releasing hormone/luteinising hormone surge in the ewe by a direct inhibitory action on oestradiol-responsive cells within the hypothalamus. J Neuroendocrinol 2005, 17(3):161-169.
• [24]Kántora O, Molnár J, Arimura A, Köves K: PACAP38 and PACAP27 administered intracerebroventricularly have an opposite effect on LH secretion. Peptides 2000, 21(6):817-820.
• [25]Leupen SM, Besecke LM, Levine JE: Neuropeptide Y Y1-receptor stimulation is required for physiological amplification of preovulatory luteinizing hormone surges. Endocrinology 1997, 138(7):2735-2739.
• [26]Battaglia DF, Krasa HB, Padmanabhan V, Viguié C, Karsch FJ: Endocrine alterations that underlie endotoxin-induced disruption of the follicular phase in ewes. Biol Reprod 2000, 62(1):45-53.
• [27]Letterie GS: Inhibition of gonadotropin surge by a brief mid-cycle regimen of ethinyl estradiol and norethindrone: possible role in in vitro fertilization. Gynecol Endocrinol 2000, 14(1):1-4.
• [28]Messinis IE, Krishnan M, Kazem R, Khadilkar S, Templeton AA: Effect of mifepristone on folliculogenesis in women treated with recombinant FSH. Clin Endocrinol 1997, 46(3):309-314.
• [29]Escudero EL, Boerrigter PJ, Bennink HJ, Epifanio R, Horcajadas JA, Olivennes F, Pellicer A, Simón C: Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2005, 90(4):2081-2088.
• [30]Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang DA, Nelson R, Richards P: Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ 1989, 298(6674):636-642.
• [31]Pantoni L, del Ser T, Soglian AG, Amigoni S, Spadari G, Binelli D, Inzitari D: Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005, 36(3):619-624.